Skip to main content
Clinical Trials/IRCT2013052113405N1
IRCT2013052113405N1CompletedPhase 2

Comperssion with the combined effects of omega _3 and citalopram for depression during menopause in postmenopausal women referred to health centers in Hamadan city in 1391: A double-blind clinical trial

Vice-chancellor for Research, Hamadan University of Medical Sciences0 sites84 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
84

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
48 years to 70 years (—)
Sex
Female

Inclusion Criteria

  • a) Age range 65-45 years; b) Should last at least 12 months of amenorrhea; c) According to DSM-IV criteria for depression are known to be; d) No history of hysterectomy, oophorectomy with radiation therapy; e) Not taking antidepressant medication and hormone therapy during the last 6 months; f) Not sensitive to herbal drug ; g) Absence of diabetes and cardiovascular disease; h) The Beck score (10-24). Exclusion criteria: a) Drug intolerance; b) Not complete treatment duration; c) The depression scores higher of 24 at follow-up period.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Vice-chancellor for Research, Hamadan University of Medical Sciences

Similar Trials